tiprankstipranks
Intellia Therapeutics CFO Glenn Goddard to step down, Edward Dulac to succeed
PremiumThe FlyIntellia Therapeutics CFO Glenn Goddard to step down, Edward Dulac to succeed
26d ago
Intellia reports proof-of-concept data for redosing CRISPR-based therapy
PremiumThe Fly
Intellia reports proof-of-concept data for redosing CRISPR-based therapy
26d ago
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
PremiumPress Releases
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
26d ago
Intellia Therapeutics Names Brian Goff to its Board of Directors
PremiumPress ReleasesIntellia Therapeutics Names Brian Goff to its Board of Directors
1M ago
Intellia Therapeutics appoints Brian Goff to board of directors
PremiumThe Fly
Intellia Therapeutics appoints Brian Goff to board of directors
1M ago
Cathie Wood’s ARK Investment bought 47K shares of Intellia Therapeutics today
PremiumThe Fly
Cathie Wood’s ARK Investment bought 47K shares of Intellia Therapeutics today
1M ago
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
PremiumPress ReleasesIntellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
2M ago
Intellia Therapeutics price target lowered to $29 from $31 at Citi
PremiumThe Fly
Intellia Therapeutics price target lowered to $29 from $31 at Citi
2M ago
Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
PremiumThe Fly
Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100